A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions
Clinical trial NCT07275814 · COMPLETED
Trial details
- NCT number
- NCT07275814
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-17
- Primary completion
- 2026-06-17
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.